1. Scrip
  2. >>New Products

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

 
• By Joseph Haas

Accelerated approval in epithelioid sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Text Starting Point and yellow pencil on bright background
Now that it has approval in ES, Epizyme will attempt to move Tazverik into larger indications

Epizyme Inc. has its first product approval with the 23 January clearance by the US Food and Drug Administration of Tazverik (tazemetostat) for non-surgical, metastatic or locally advanced epithelioid sarcoma, but that indication largely is meant to clear the way for the first-in-class EZH2 inhibitor to obtain approval for follicular lymphoma and other larger oncology indications.

“We've always viewed this as a way to get into the market and build over time and be prepared for the follicular lymphoma launch,” CEO Robert Bazemore told a same-day investor call

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

More from Scrip

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

 
• By Joseph Haas, Xu Hu, Anju Ghangurde, and Lisa Takagi

Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.